Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder

British Journal of Urology

Volumn 79, Issue 1, 1997, Pages 78-84

  Chaudhary, K S ^a,b,c,d,e   Lu, Q L ^a,b,c,d,e   Abel, P D ^a,b,c,d,e   Khandan Nia, N ^a,b,c,d,e   Shoma, A M ^a,b,c,d,e   Baz, M E L ^a,b,c,d,e   Stamp, G W H ^a,b,c,d,e   Lalani, E N ^a,b,c,d,e  

^a Department of Histopathology ^*  (Egypt)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MANSOURA UNIVERSITY   (Egypt)

^d MANSOURA UNIVERSITY   (Egypt)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

bcl 2; Bladder cancer; p53; Schistosomiasis

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; FEMALE; GENE OVEREXPRESSION; HUMAN; HYPERPLASIA; IMMUNOREACTIVITY; MALE; METAPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISTOSOMIASIS; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR DIFFERENTIATION; UROTHELIUM;

EID: 0031400916     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.30717.x     Document Type: Article

References (39)

1. Ferguson AR. Associated bilharziasis and primary malignant disease of the urinary bladder, with observations in the series of forty cases. J Path Bact 1911; 16: 76-94
2. El-Boulkainy MN, Mokhtar NM, Ghoncim MA, Hussein MH. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 1981; 48: 2643-8
3. Kitinya JN, Lauren PA. Eshleman LJ, Paljarvi L. Tanaka K. The incidence of squamous and transitional cell carcinomas of the urinary bladder in northern Tanzania in areas of high and low levels of endemic schistosoma haematobium infection. Trans R Soc Trop Med Hyg 1986; 80: 935-9
4. Tsujimoto Y. Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14:18) chromosome translocation. Science 1984: 226: 1097-9
5. Lu QL, Abel P. Foster CS, Lalani EN. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 1996; 27: 102-10
6. Zhong LT, Sarafian T. Kane DJ et al. bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci USA 1993; 90: 4533-7
7. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14:18). Nature 1991; 349: 254-6
8. Nunez G. London L. Hockenbery D, Alexander M. McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990; 144: 3602-10
9. Strasser A, Harris AW. Bath ML. Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-3
10. Lu QL, Elia G. Lucas S. Thomas JA. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993; 53: 29-35
11. 1 Colombel M. Symmans F. Gil S et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormonerefractory human prostate cancers. Am J Pathol 1993: 143: 390-400
12. Gee JM. Robertson JF. Ellis IO et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994; 59: 619-28
13. Lane DP. Cancer. p53, guardian of the genome [news; comment] [see comments]. Nature 1992; 358: 15-6
14. Mercer WE, Avignolo C, Baserga R. Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies. Mol Cell Biol 1984; 4: 276-81
15. Casson AG, Manolopoulos B. Troster M et al. Clinical implications of p53 gene mutation in the progression of Barren's epithelium to invasive esophageal cancer. Am J Surg, 1994; 167: 52-7
16. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-8
17. Hollstein M. Sidransky D. Vogelstein B. Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53
18. Lohmann D. Ruhri C. Schmitt M. Graeff H. Hofier H. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives. Diagn Mol Pathol 1993; 2: 36-41
19. Harris CC, Hollstein M. p53 tumour suppressor gene. PPO Updates 1992; 6: 1-12
20. Spruck CHr. Ohneseit PF. Gonzalez Zulueta M et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784-8
21. Sidransky D. Von Eschenbach A. Tsai YC et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252: 706-9
22. Fujimoto K. Yamada Y, Okajima E et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52: 1393-8
23. Olumi AF, Tsai YC, Nichols PW et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder, Cancer Res 1990; 50: 7081-3
24. Soini Y, Turpeenniemi Hujanen T, Kamel D et al. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 1993; 68: 1029-35
25. Kamel D. Soini Y. Nuorva K et al. p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions. Virchows Arch 1994; 424: 349-55
26. Warren W. Biggs PJ. el Baz M. Ghoncim MA, Stratton MR, Venitt S. Mutations in the p5 3 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutalional spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis 1995; 16: 1181-9
27. Haldar S. Negrini M, Monne M, Sabbioni S. Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54: 2095-7
28. Leek RD, Kaklamanis E. Pezzella F. Gatter KC, Harris AL, bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994; 69: 135-9
29. Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F. bcl-2. p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer 1996; 73: 139-43
30. Lu QL, Poulsom R, Wong L. Hanby AM. Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol 1993; 169: 431-7
31. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci US 1991; 88: 6961-5
32. Compel A, Sabourin JC, Martin A et al. Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 1994; 144: 1195-202
33. Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasia. Cancer 1994; 73: 2900-4
34. Nakagawa K, Yamamura K, Maeda S, Ichihashi M. bcl-2 expression in epidermal keratinocytic diseases. Cancer 1994; 74: 1720-4
35. Bronner MP, Culin C, Reed JC, Furth EE, The bcl-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995; 146: 20-6
36. Hall PA, Lane DP, p53 in tumour pathology: can we trust immunohistochemistry? - Revisited! [editorial] [see comments]. J Pathol 1994; 172: 1-4
37. Wang Y, Szekely L, Okan I, Klein G, Wiman KG, Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993; 8: 3427-31
38. Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805
39. Sinicrope FA, Ruan SB, deary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995; 55: 237-41